Alzheimer's disease features amyloid-beta plaques and tau tangles, driving neuronal loss and cognitive decline. Stem-cell approaches address several pathways: placental mesenchymal stem cells are studied for neuroprotection — secreting anti-inflammatory and growth factors that may slow neuronal death — while exosomes derived from stem cells are explored as carriers for therapeutic molecules across the blood-brain barrier and as modulators of amyloid and tau biology. The rationale builds on evidence that stem-cell products reduce neuroinflammation and may support hippocampal neuroplasticity. Reversing established pathology and achieving adequate brain delivery remain unsolved; early trials are small and heterogeneous, with uncertain durability.
Forty-one registered trials and 9 recruiting studies investigate stem-cell therapy in Alzheimer's. Small cohorts describe modest cognitive-score changes over 6–12 months; most are uncontrolled. Some show shifts in cerebrospinal-fluid or PET amyloid/tau markers, with less consistent functional gains. No trial has prevented decline or shown reversal of neuronal loss. Approved amyloid-targeting antibodies (lecanemab, aducanumab) show modest slowing of early decline — stem-cell benefit is not proven to match them.
Indicative European costs are roughly €3,500–€7,000 per course; exosome-based protocols can reach €5,000–€8,000 due to manufacturing complexity. Pre/post neuroimaging (MRI, PET) adds further expense, and multi-dose protocols are common. For context, approved Alzheimer's drugs range from inexpensive symptomatic agents to costly antibody infusions — the stem-cell figure is indicative and less evidence-backed.
Cell therapy for Alzheimer's Disease is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Alzheimer's Disease programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Alzheimer's Disease overview · Alzheimer's Disease cost →
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita